Home › Funds › BRAIDWELL LP › MBX
BRAIDWELL LP position in MBX
MBX BIOSCIENCES INC COM · Health Care
BRAIDWELL LP reported holding 710,880 shares of MBX (MBX BIOSCIENCES INC COM) in its Q2 2026 13F filing — a position valued at US$39.2M, representing 1.54% of its reported portfolio and ranking #24 among its reported holdings. BRAIDWELL LP has disclosed MBX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How BRAIDWELL LP's MBX position evolved
BRAIDWELL LP first disclosed a stake in MBX in Q4 2025 at 1,018,600 shares (US$32.1M). The position peaked in Q1 2026 at 1,492,467 shares, worth US$44.6M. Across 3 filings, BRAIDWELL LP increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 710,880 shares valued at US$39.2M — a reduction of -781,587 shares quarter over quarter.. Notable position changes include a 47% increase in Q1 2026 (shares rose 85% over the following quarter), a 52% trim in Q2 2026 (shares rose 6% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 1.02M | $32.13M | New |
| Q1 2026 | 1.49M | $44.55M | Add |
| Q2 2026 | 710.88K | $39.24M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MBX and 13F data
MBX (MBX BIOSCIENCES INC COM) is a Health Care company. 73 other funds we track also report a position in MBX — the largest reported positions include Frazier Life Sciences Management, L.P. (US$367.2M), NEA Management Company, LLC (US$199.5M), ORBIMED ADVISORS LLC (US$189.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MBX
- Frazier Life Sciences Management, L.P. 6.65M sh · $367.19M · Q2 2026
- NEA Management Company, LLC 3.61M sh · $199.52M · Q2 2026
- ORBIMED ADVISORS LLC 3.43M sh · $189.27M · Q2 2026
- Paradigm Biocapital Advisors LP 2.51M sh · $138.44M · Q2 2026
- NVP Associates, LLC 2.14M sh · $117.93M · Q2 2026
- Deep Track Capital, LP 1.73M sh · $95.64M · Q2 2026
- Aaron Wealth Advisors LLC 1.18M sh · $68.92M · Q3 2026
- Kynam Capital Management, LP 934.80K sh · $51.60M · Q2 2026
- Parkman Healthcare Partners LLC 800.17K sh · $44.17M · Q2 2026
- TCG Crossover Management, LLC 650.00K sh · $35.88M · Q2 2026
- Cormorant Asset Management, LP 550.00K sh · $30.36M · Q2 2026
- Soleus Capital Management, L.P. 515.28K sh · $28.44M · Q2 2026
More on BRAIDWELL LP
FAQ
How long has BRAIDWELL LP held MBX?
BRAIDWELL LP has disclosed MBX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is BRAIDWELL LP's current position in MBX?
As of Q2 2026, BRAIDWELL LP holds 710.88K shares of MBX (MBX BIOSCIENCES INC COM), valued at $39.24M, representing 1.54% of its reported portfolio and ranking #24.
Has BRAIDWELL LP been buying or selling MBX?
In the latest 13F filing (Q2 2026), BRAIDWELL LP reduced its position in MBX. The position peaked in Q1 2026 at 1.49M shares.
Which other funds hold MBX?
Other major institutional holders of MBX include Frazier Life Sciences Management, L.P., NEA Management Company, LLC, ORBIMED ADVISORS LLC, among 73 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.